Search results
2 kwi 2024 · Universal vaccination: To reduce community transmission and protect individuals with HIV, this committee agrees with the CDC recommendations for universal vaccination against COVID-19 for adults (≥18 years old) with HIV, regardless of prior history of COVID-19 infection.
19 lip 2024 · Eligible participants were healthy women (assigned female sex at birth) aged 18–35 years who had had sexual intercourse with a male partner two or more times in the 30 days before screening, were at increased risk of acquiring HIV-1, and were HIV-1-negative and HIV-2-negative.
10 sty 2024 · For people with HIV without risk factors, waiting for a CD4 count >200 cells/mm 3 is an option. Assess antibody response 1 to 2 months after completion of the series. If negative, revaccinate when the CD4 count is >200 cells/mm 3 (BIII).
20 gru 2023 · This Review discusses lessons learned from clinical trials of HIV-1 vaccines, current technologies that are being explored, and future considerations in the development of a safe and effective HIV-1 vaccine.
HIV is a virus that remains a major health concern and results in an infection that has no cure even after over 30 years since its discovery. As such, HIV vaccine discovery continues to be an area of intensive research. In this review, we summarize the most recent HIV vaccine efficacy trials, clinical trials initiated within the last 3 years ...
23 paź 2023 · Recent advances in HIV immunogen design have taken the field a step closer to triggering the rare precursors of broadly neutralising antibodies, which are widely assumed to be necessary for a vaccine.
HIV is a virus that remains a major health concern and results in an infection that has no cure even after over 30 years since its discovery. As such, HIV vaccine discovery continues to be an area of intensive research. In this review, we summarize the most recent HIV vaccine efficacy trials, clinic …
